Bridging the Development–Manufacturing Gap to Achieve QbD and PAT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bridging the Development–Manufacturing Gap to Achieve QbD and PAT


Equipment and Processing Report

Quality by design (QbD) helps pharmaceutical companies achieve the US Food and Drug Administration’s desired state of manufacturing. The agency intends QbD as a framework to foster process understanding based on science. The goals of QbD are reducing risks and saving time and money by designing processes with reduced variability and low technology-transfer risk early in the manufacturing cycle. Process development (PD) and manufacturing teams can collaborate by developing a design space and using process analytical technology tools and QbD principles with their combined experience to achieve manufacturing-process excellence.

To implement QbD and reduce business risks, teams should begin QbD collaboration early during PD. I mproving the design of a process before manufacturing begins has numerous benefits.

QbD entails scientifically designing product- and process-performance characteristics into the process to meet specific outcomes rather than deriving these characteristics empirically from the performance of test batches. Operating parameters are derived from a combination of previous knowledge and experimental assessment, along with a cause-and-effect model that links critical process parameters to the critical quality attributes.

Today's manual data access and disconnected analytics (sometimes called “spreadsheet madness”) are inconsistent with the goals of QbD. A process is well understood when the following three criteria are met:

  1. All critical sources of variability are identified and explained
  2. Quality is designed into the process so that the process itself manages variability
  3. Product-quality attributes can be accurately and reliably predicted.

It follows that accurate and reliable predictions reflect process understanding and, therefore, risk is inversely proportional to process understanding.

On-demand access to specific data that are available in real time in a collaborative investigational-analytics environment is a fundamental requirement for successful collaboration between the PD and manufacturing teams. Providing interactive, on-demand access for end users to data from disparate systems (e.g., laboratory information management systems, historians, and manufacturing execution systems) in one combined form allows investigations for cause-and-effect relationships that link critical process parameters to critical quality attributes to be completed in minutes instead of months. Analytics should include descriptive (i.e., what happened) as well as investigational (i.e., why it happened) capabilities. A ll types of data—including discrete (off-line), continuous (on-line), and paper-based data—should be included to make meaningful analyses possible.

Collaboration must enable productivity and compliance improvements that transcend logistical and organizational issues. It also must allow nonprogrammers and nonstatisticians to complete tasks quickly and effectively as a team.

Significant business, quality-compliance, and regulatory benefits can be achieved when teams collaborate by using available technology for on-demand data access and analysis. P ayoffs include:

  • Reduced batch failures, final-product testing, and batch-release costs
  • Lower operating costs resulting from fewer failures and deviation investigations
  • Increased predictability of manufacturing output and quality
  • Reduced inventory costs from raw material, work in process, and finished product
  • Faster technology transfer between development and manufacturing
  • Faster regulatory approval of new-product applications and process changes
  • Fewer, shorter, and less-costly regulatory inspections

In summary, appropriate technologies such as manufacturing process intelligence software enable PD and manufacturing teams to achieve shared QbD goals. Successful collaboration requires the flow of process data and information from PD into manufacturing. The lessons that manufacturing learns must be transmitted to PD, and the right data access, aggregation, analysis, and collaboration software tools must be in place to allow information to be exchanged in both directions. Only then can PD and manufacturing function as a single team with the best outcomes.

Justin O. Neway, PhD, is executive vice-president and chief science officer at Aegis Analytical Corporation, jneway@aegiscorp.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here